[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"streptococcal-infections\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:streptococcal-infections":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,76,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100642701","a-clinical-trial-of-the-13-valent-pneumococcal-polysaccharide-conjugate-vaccine-crm197tetanus-toxoid-100642701",false,"NCT07648641","A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197\u002FTetanus Toxoid)","Phase IV Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197\u002FTetanus Toxoid)","Inclusion Criteria:\n\n* Participants in the 2-month-old (minimum 6 weeks) group from the previous Phase III clinical trial of the 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197, TT vector) (Protocol No.: CS-CTP-PCV)\n* The legal guardian or authorized representative is willing to provide identification documents\n* The legal guardian or authorized representative has provided informed consent, voluntarily signed the informed consent form, and is able to comply with the requirements of the clinical study protocol\n* The interval since the last dose of the primary vaccination series is ≥4 years\n\nExclusion Criteria:\n\n* Failure to complete blood draws at 1 and 2 years post-vaccination\n* Administration of any pneumonia vaccine after completion of the full vaccination series\n* Body temperature ≥37.3°C\n* Any other factors deemed by the investigator to render the participant unsuitable for participation in the clinical trial",true,"ALL","5 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","This clinical study will enroll 100 participants from the 2-month-old (minimum 6 weeks) group who previously participated in the Phase III clinical trial of the 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197, TT vector) (Protocol No.: CS-CTP-PCV), with 50 participants in each of the treatment and control groups, and who have completed blood sample collection for the 1-year and 2-year immunogenicity studies. All participants will have 3.0-3.5 mL of venous blood collected for the immunogenicity study.",[25,26,27],"Pneumococcal Infections","Streptococcal Infections","Bacterial Infections",[29,30,25,31],"PCV13","13 valent Pneumococcal conjugate vaccine","Immune persistence","NOT_YET_RECRUITING","2026-06-10",{"date":35,"type":36},"2026-06-15","ACTUAL",{"date":38,"type":21},"2026-07-01",{"date":40,"type":21},"2027-12-01",{"name":42,"class":43},"CanSino Biologics Inc.","INDUSTRY",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100594310","phase-3-a-study-to-evaluate-the-immunogenicity-and-safety-of-13-valent-pneumococcal-conjugate-vaccine-pcv13i-in-healthy-infants-aged-2-months-minimum-6-weeks-100594310","NCT07017777","A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)","A Phase III, Observer-blind, Randomized Controlled Trial to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)","Inclusion Criteria:\n\n* Healthy infants with stable clinical conditions aged 2 months (42-90 days) at the time of screening, based on medical history and clinical assessment by the investigator. Infants will be eligible starting from the day they turn 6 weeks of age.\n* Infant's parent or legal guardian must be able and willing to provide informed consent for the infant's participation in the study.\n* Participants and their parent or legal guardian must demonstrate the ability to comply with all trial procedures and be available for the entire follow-up duration.\n* The infant's parent or legal guardian must have an easily identifiable and stable place of residence within the study area, be available for the duration of trial participation, and have access to a reliable means of telephone contact for communication with the study team.\n\nExclusion Criteria for the first dose:\n\n* Infants born at \\\u003C35 weeks of gestation.\n* Infants who have previously received any pneumococcal vaccine.\n* Infants currently participating in or who have recently participated in another interventional clinical trial.\n* Infants with an axillary temperature of ≥37.8°C at the time of enrollment (the participant must be deferred until recovery. The visit may be rescheduled when this criterion is met.)\n* Infants with any congenital abnormalities, chronic medical conditions, or genetic disorders, severe malnutrition, inherited disease and others, that in the investigator's judgment, may interfere with the study outcomes.\n* History of anaphylactic shock\n* History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the experimental and control vaccine\n* History of epilepsy and convulsions.\n* Have received immunosuppressive treatment, cytotoxic treatment, systemic steroid treatment for more than 2 weeks, etc. (excluding local treatment, surface treatment of acute non-concurrent dermatitis, or spray treatment of allergic rhinitis).\n* Received or planned to receive blood\u002Fplasma products or immunoglobulins throughout the study period or prior to study vaccination.\n* History of coagulation disorders or blood conditions that could cause anemia or excess bleeding as judged by the investigator.\n* Infants with known or suspected immunodeficiency, as determined by medical history and\u002For physical examination.\n* Administration of other vaccines within 7 days prior to enrollment.\n* Any history or current evidence of a condition or therapy that could confound study results, interfere with participation, or is not in the best interest of the participant, as judged by the investigator.\n* The participant is a direct descendant (child or grandchild) of any person employed by the Sponsor, the contract research organization (CRO), the investigator, or study site personnel.\n* Any other condition or situation that, in the investigator's judgment, might interfere with the study or pose additional risks to the participant.\n\nIndividual termination criteria for subsequent doses:\n\n* Severe allergic reaction after the previous vaccination.\n* Serious adverse events caused by the previous vaccination that is not suitable for subsequent vaccination(s) as judged by the investigator.\n* Newly identified symptoms or newly occurred cases after the first vaccination that do not meet the inclusion criteria for the first dose, or that meet the exclusion criteria for the first dose. The decision to discontinue participation is determined by the investigator.\n* Other reasons for exclusion considered by the investigator.","6 Weeks","2 Months",{"count":54,"type":21},600,"INTERVENTIONAL",[57],"PHASE3","This is a Phase 3 randomized, observation-blinded, active-controlled, parallel-group clinical trial designed to evaluate the immunogenicity, safety, and functional antibody response of the experimental vaccine versus the control vaccine in healthy Thailand infants vaccinated at a 2+1 schedule (2 months, 4 months and 12-15 months). The trial will enroll approximately 600 healthy infants aged 2 months (at least 6 weeks) who will be randomly assigned in a 1:1 ratio to receive either the experimental or control vaccine, with 100 in each group (200 in total) randomized to subgroups and subject to additional immunogenicity assessments. All participants will be evaluated for solicited adverse events for 7 days and unsolicited adverse events for 30 days post each vaccination. Immunogenicity evaluation will be performed in all participants at baseline and post the booster dose, while the sub-cohort participants will be evaluated for post primary series immunogenicity additionally.",[25,26,27],[61,30,62,63,64,65],"PCV13i","Pneumococcal infections","2 months of age","Safety","Immunogenicity","RECRUITING","2026-02-25",{"date":69,"type":36},"2026-02-27",{"date":71,"type":36},"2025-11-14",{"date":73,"type":21},"2028-05-15",{"name":42,"class":43},3,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":101},"100619326","factors-associated-with-mortality-in-streptococcal-anginosus-bacteremia-100619326","NCT07343167","Factors Associated With Mortality in Streptococcal Anginosus Bacteremia","SGA","Inclusion Criteria:\n\n* Major subject (≥18 years old)\n* Hospitalized between January 1, 2019, and December 31, 2024, in one of the participating centers\n* Having presented during the study period at least one positive blood culture for Streptococcus anginosus, Streptococcus constellatus, or Streptococcus intermedius in a laboratory at a participating center\n\nExclusion Criteria:\n\n* Refusal to participate in the study","18 Years",{"count":85,"type":21},400,"Streptococcal anginosus infections (S. constellatus, S. anginosus, and S. intermedius) are characterized by their severity, linked to high mortality and frequent infectious complications. Several studies in the literature highlight this severity, with mortality rates estimated at around 15%.\n\nThe aim of this research is to identify the factors associated with mortality in Streptococcal anginosus bacteremia.",[26],[26,89,90],"Streptococcal Anginosus Bacteremia","Streptococcal anginosus infections","2026-01-06",{"date":93,"type":36},"2026-01-15",{"date":95,"type":36},"2025-09-08",{"date":97,"type":21},"2027-03-08",{"name":99,"class":100},"University Hospital, Strasbourg, France","OTHER",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":16,"sex":17,"minAge":83,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":55,"phases":112,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100599531","phase-1-a-study-to-evaluate-safety-reactogenicity-and-immunogenicity-of-the-gsk-4-component-strep-a-vaccine-with-aluminum-hydroxide-alum-or-as37-in-healthy-young-adults-100599531","NCT07085702","A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults","A Phase 1 Randomized, Placebo-controlled, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Vaccine Against Group A Streptococcus Pyogenes (Strep A) With Alum or AS37 in Healthy Adults 18 to 25 Years of Age in Australia","Inclusion Criteria:\n\n* Participants, who, in the opinion of the Investigator, can and will comply with the requirements of the protocol (e.g., completion of electronic diaries \\[eDiaries\\], return for follow-up visits).\n* Written or witnessed\u002Fthumb-printed informed consent obtained from the participant prior to performance of any study-specific procedure.\n* Healthy participants as established by medical history, clinical examination, and laboratory assessments.\n* Satisfies all screening requirements.\n* Male and female participants between and including 18 and 25 years of age at the time of informed consent.\n* Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as premenarche, postmenopause, or had current bilateral tubal ligation or occlusion, hysterectomy, or bilateral ovariectomy.\n* Female participants who are of childbearing potential may be enrolled in the study if the participant:\n\n  * has practiced adequate contraception for 1 month prior to study intervention administration, and\n  * has a negative pregnancy test on the day of study intervention administration, and\n  * has agreed to continue adequate contraception during the entire study intervention administration period and for 1 month after completion of the study intervention administration series.\n* Male participants who are sexually active with a female partner of childbearing potential are eligible to participate if they agree to have their partner use a highly effective method of contraception for 1 month prior to the first study intervention administration until 1 month after completion of the study intervention administration series.\n* Male participants must refrain from donating sperm for 1 month prior to the first study intervention administration until 1 month after completion of the study intervention administration series.\n* Participants seronegative for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C at Screening.\n\nExclusion Criteria:\n\n* History of rheumatic fever or rheumatic heart disease during the lifetime of the participant as confirmed during interview with the participant or as documented in medical records.\n* Recent history of pharyngitis in the last four (4) weeks will be excluded. These participants can be rescreened once the recent pharyngitis passes the 4-weeks period. Participants with symptoms of acute pharyngitis at Screening will be tested with a Strep A rapid antigen test. Those with positive results will be excluded.\n* Progressive, unstable, or uncontrolled clinical conditions.\n* History (known or suspected) of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.\n* Hypersensitivity (e.g., allergy) to medicinal products or medical equipment anticipated to be used in this study.\n* Clinical conditions that represents a contraindication for IM vaccination or blood draws.\n* Any behavioral or cognitive impairment or psychiatric disease that, in the opinion of the Investigator, may interfere with the participant's ability to participate in the study.\n* Acute disease and\u002For fever (defined as temperature \\>=38.0°C) at the time of enrollment.\n* Any Grade \\>=2 and\u002For clinically significant hematological and\u002For biochemical laboratory abnormality.\n* Any echocardiographic\u002FDoppler Echo findings consistent with carditis at Screening.\n* Recurrent history or uncontrolled neurological disorders or seizures.\n* Medical history or family history of autoimmune disease and other pIMDs.\n* Family history of acute rheumatic fever.\n* Acute or chronic illness, or clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality.\n* Any other clinical condition that might pose additional risk to the participant due to participation in the study.\n* Administration of long-acting immune-modifying drugs (e.g., infliximab) at any time prior to the administration of the first dose of study intervention(s) or planned administration during the study period.\n* Prior receipt of an experimental Strep A vaccine.\n* Use of any investigational or nonregistered product (drug, vaccine, or medical device) other than the study interventions during the period starting 30 days before the first dose of study intervention (Day -30 to Day 1), or their planned use during the study period.\n* Receipt of a vaccine not foreseen by the study protocol administered during the period starting at 21 days before the first dose of study intervention (28 days before the first dose, in case of live vaccines) and ending after the last dose of study intervention administration.\n* Administration of immunoglobulins and\u002For any blood products or plasma derivatives, or bone marrow transplantation, during the period starting 3 months before administration of the first dose of study intervention(s) or planned administration during the study period.\n* Chronic administration (defined as \\>14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first dose of study intervention. For corticosteroids, this means prednisone equivalent \\>=20 mg\u002Fday for adult participants. Inhaled, topical, intra-articular, and intranasal steroids are allowed.\n* Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug, vaccine, or invasive medical device).\n* Pregnant or lactating female participant.\n* Participant who is planning to become pregnant or planning to discontinue contraceptive precautions.\n* History of or current chronic alcohol consumption and\u002For drug abuse.\n* Any study personnel or their immediate dependents, family, or household members.","25 Years",{"count":111,"type":21},108,[113],"PHASE1","The purpose of this study is to assess the safety of 3 doses of 2 new Strep A vaccine formulations, one with an Alum adjuvant, and the other with AS37 adjuvant. The Strep A vaccine will be tested for the first time in humans, in healthy young adults 18 to 25 years of age. The study will also assess if the vaccines have any immediate reactions and if they induce an immune response. A low, medium, and high dose of each formulation of the vaccine will be assessed in sequence.",[26],[117,118,64,119,65,120,121],"Strep A","Streptococcus pyogenes","Reactogenicity","Healthy Adults","Australia","2025-08-06",{"date":124,"type":36},"2025-08-11",{"date":126,"type":36},"2025-07-31",{"date":128,"type":21},"2026-11-30",{"name":130,"class":43},"GlaxoSmithKline",2]